Affymax Plans For Peginesatide Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech is making plans with its Japanese partner for the launch of its new ESA that is awaiting approval.
You may also be interested in...
3SBio Prepares For Larger Than Expected Price Cuts; Enters Dialysis Market With DaVita Deal: China Earnings Roundup (Part 3)
As price cuts loom, China’s top biotech looks to fuel EPO sales in China by teaming up with a leading U.S. dialysis provider, in a deal reminiscent of Amgen’s steps in the U.S.
Affymax's Peginesatide May Be Tough Sell To ODAC As ESAs Cast Long Showdow
Safety concerns over erythropoiesis-stimulating agents seem to extend to Affymax's peginesatide, and since it lacks an efficacy edges over these drugs in treating anemia due to chronic kidney disease, an approval basis is unclear.
Affymax's Share Price Stumbles On Questionable Phase III Hematide Data
Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.